Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

DrStockPick.com Watch List!

My Picks for Wednesday September 16, 2009, are:

**************************************************************

MVIS, Microvision, Inc.

MVIS is a global leader in innovative ultra-miniature projection display and image capture products for mobility applications

Today was the commercial introduction of the world’s first laser-based pico projector, called SHOW WX™, based on its proprietary PicoP® display engine technology.

The MVIS pico projector uses the revolutionary laser-based PicoP display engine that delivers large, colorful, bright, and vivid images that are always in focus, regardless of projection distance. The accessory product is a simple plug-n-play pico projector for people on-the-go who

...

Below are 12 extreme FDA trades for 11 companies with market caps below $200M which have pending new drug product decisions or other meetings/milestones scheduled with the FDA that are expected to have a major impact on each of the underlying stock prices as the PDUFA decision dates approach and the decision is ultimately announced. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in extreme FDA and Clinical Trial Calendar trades, which are highlighted in periodic articles at BioMedReports.com.

Hemispherx Biopharma [HEB: 1.36, -0.10 (-6.85%)]: Ampligen (Poly I: Poly C12U) NDA (three month PDUFA decision date delay was announced on 2/18/09 as additional data was submitted by HEB within three months of original decision date). Ampligen is an experimental treatment for chronic fatigue syndrome (which has no

...

Highlighted companies include Novo Nordisk (NVO), Alkermes (ALKS), Eli Lilly (LLY) and Amylin (ALMN).

Late Thursday, an FDA panel reviewing Novo Nordisk's (NVO) Liraglutide application for type II diabetes expressed concern over a study that indicated it might trigger thyroid cancer tumors in rodents.

Alkermes (ALKS) and Eli Lilly (LLY)/Amylin (ALMN) are also co-developing a similar drug exenatide LAR, a long-acting version of Amylin's popular medication Byetta for type II diabetes.

Both liraglutide and exenatide belong to the same class of drugs called GLP-1s. So far, according to data from both preclinical and clinical studies, we think Exenatide LAR may have a better safety profile than liraglutide, but we are not sure if the FDA will exert tough rule on the safety concerns of Exenatide.

Currently, Exenatide is under 4 phase III studies (DURATION-1, 2, 3 and 4). The extension of

...

R&D Leads to Higher Returns for Top 20 Health Innovators The accompanying table includes statistics and the top 20 rated companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the trailing 12-month period for either an original new drug product or medical device. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies which receive original PMA approvals for new medical devices are included in the index, excluding the less rigorous and more numerous 510(k) applications. The goal of the index is to ...